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incidence
Breast cancer is the most common cancer in women in many
countries, including developing countries. The crude incidence
in the European Union is 109.8/100 000, the mortality is 38.4/
100 000 women/year. Since 1990 the incidence rate has
increased 1.5% annually. Due to advances both in early
detection and in adjuvant treatment, mortality rates from
breast cancer have been decreasing steadily in most western
countries since the early 1990s. However, it is still the leading
cause of cancer mortality in women. Approximately 6% of
breast cancers are metastatic at diagnosis with a 5-year survival
rate of 21%. Depending on prognostic factors, in the worst
scenario, up to 30% of node-negative and up to 70% of node-
positive breast cancers will relapse. The prevalence of metastatic
disease is high because many women live with the disease for
several years.
diagnosis
 Clinical suspicion must be confirmed by radiologic and/or
scintigraphic examinations and blood tests.
 Effort should be made to obtain histopathological
confirmation particularly in the situation of an isolated
metastatic lesion. Biological markers important for treatment
decisions, such as hormonal receptors and HER-2 status,
should be evaluated in the metastatic lesion whenever possible.
staging and risk assessment
 Complete history, including menopausal status and co-
morbidities; detailed history of the primary tumor, its
biology, management and last normal follow-up (Table 1).
 Detailed physical examination including performance status.
 Blood tests: complete blood count, liver and renal function
tests, alkaline phosphatase, calcium, tumor marker CA 15-3.
 Chest X-ray or computed tomography (CT), abdominal
ultrasound or CT should be used to identify visceral disease.
 Bone scintigraphy, with confirmation of lesions by X-ray/CT/
magnetic resonance imaging (MRI).
 CT and/or MRI of the central nervous system should be
symptom driven.
 PET/PET–CT may be useful for identifying the site of relapse,
particularly when traditional imaging methods are equivocal
or conflicting. It may also be helpful to identify an isolated
metastatic lesion, since this subset of patients may benefit
from a more aggressive multidisciplinary approach.
 Estrogen and progesterone receptors, HER-2 receptors and
proliferationmarkers of themetastatic lesion should be obtained,
if possible, and particularly if not available on the primary tumor.
treatment
 Isolated local–regional recurrence should be treated like
a new primary with a curative intent including ‘secondary’
adjuvant treatment modalities as appropriate [II, B].
 The management of metastatic breast cancer (MBC) should
involve all appropriate specialities in a multi/interdisciplinary
team (medical, radiation, surgical and imaging oncologists,
palliative care specialist, psychosocial support), and patients
should be offered personalized appropriate psychosocial,
supportive and symptom-related interventions as a routine
part of their care.
 There are few proven standards of care in MBC management,
therefore well-designed, independent, prospective
randomized trials are a priority.
 The vast majority of MBC is incurable and hence the main
treatment goal is palliation, with the aim of maintaining/
improving quality of life, and possibly improving survival.
 The realistic treatment goals should be discussed with the
patient and her family from the beginning and the patient
should be encouraged to actively participate in all decisions.
Patient’s preferences should always be taken into account.
 Systemic treatment options for MBC are endocrine therapy,
chemotherapy and biological agents such as trastuzumab and
lapatinib [I, A].
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 Radiation therapy is an integral part of palliative treatment.
 For limited metastatic presentations surgery may be
considered.
 Bisphosphonates should be used for the treatment of
hypercalcemia, to palliate symptoms and decrease risk of
bone events from clinically evident bone metastases [I, A].
The timing and optimal duration of bisphosphonates are
unknown.
patients with luminal-type breast cancer (hormone
receptor-positive breast cancer)
 Endocrine therapy is the preferred option except if clinically
aggressive disease mandates a quicker response or if there are
doubts regarding the endocrine responsiveness of the tumor.
Available endocrine agents are listed in Table 2.
 The choice of endocrine agent should be individualized
according to the patient’s safety profile, co-morbidities and
tumor biology.
 Maintenance with hormonal treatment after chemotherapy
has not been established, but is a reasonable approach.
 Concomitant chemo-hormonal therapy is discouraged.
premenopausal patients. If no prior adjuvant tamoxifen or if
discontinued for >12 months: tamoxifen with ovarian ablation
(luteinizing hormone releasing hormone analogue or surgery)
is the preferred option [I, B]. Otherwise, third-generation
aromatase inhibitors may be considered after or concomitantly
with ovarian ablation.
postmenopausal patients. If no prior adjuvant third-generation
aromatase inhibitors (anastrozole, letrozole, exemestane) these
are the preferred option since they have consistently shown
superior results to tamoxifen as first-line therapy in terms of
response rate, time to progression and, for letrozole, in 2-year
overall survival [II, A]. However, tamoxifen remains an
acceptable first-line therapy in selected cases.
Second-line hormone therapy may include tamoxifen,
anastrozole, letrozole, exemestane, fulvestrant, megestrol
acetate and androgens. No definitive recommendation can be
given for endocrine treatment cascade, and particularly, the
best option after progression on a third-generation aromatase
inhibitor is currently unknown.
Patients with clear evidence of endocrine resistance should be
offered chemotherapy or participation into clinical trials.
patients with basal-type breast cancer (hormone
receptor-negative breast cancer)
 Patients having hormone receptor-negative tumors are
candidates for cytotoxic chemotherapy. Available agents/
regimens are listed in Table 3.
 The only standard of care with level 1 evidence is the use of
a taxane-based regimen as first-line therapy in patients
progressing after adjuvant anthracycline-based chemotherapy
[I A]. The selection of the best agent/regimen should be
individualized and should take into account the factors listed
in Table 1.
 For the majority of patients, overall survival outcomes from
the sequential use of single cytotoxic drugs is equivalent to
that of combination chemotherapy, with less associated
toxicity and better quality of life. Therefore, in the absence of
the need for a rapid and significant response for symptom
control or life-threatening disease, preference should be given
to the sequential use of a single cytotoxic agent. However,
very few randomized clinical trials have correctly addressed
this question and there is an urgent need for a well-designed,
prospective randomized trial to compare sequential single-
agent with combination chemotherapy as first-line therapy of
MBC.
 There is no standard approach for patients requiring second-
or further-line treatment since there are no data supporting
the superiority of any particular regimen.
 Duration of each regimen and number of regimens should be
tailored to each individual patient. Continuing beyond third-
line may be justified in patients with good performance status
and response to previous chemotherapy.
 High-dose chemotherapy should not be proposed.
patients with HER-2-positive breast cancer
 Patients should be treated with trastuzumab with or without
chemotherapy [II, B].
 Trastuzumab should be offered early to all HER-2-positive
MBC patients.
Table 1. Factors to consider in risk assessment and treatment decision
making for MBC
Disease-related factors Patient-related factors
Disease-free interval Patient’s preferences
Previous therapies and response Biological age
Biological factors (hormonal
receptors, HER-2)
Menopausal status
Tumor burden (number and site
of metastases)
Co-morbidities and performance
status
Need for rapid disease/symptom
control
Socio-economic and psychological
factors
Available therapies in the patient’s country
Table 2. Available endocrine therapies for MBC
Class of agent
Selective estrogen receptor modulators Tamoxifen; toremifene
Estrogen receptor down-regulator Fulvestrant
Luteinizing hormone-releasing hormone
analogues
Goserelin; leuprorelin
Third-generation aromatase inhibitors
Non-steroidal Anastrozole, letrozole
Steroidal Exemestane
Progestins Medroxyprogesterone acetate;
megestrol acetate
Androgens
Anabolic steroids, e.g. nandrolone
decanoat
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 Cardiac monitoring should be performed before and while on
trastuzumab therapy.
 Trastuzumab in combination with endocrine therapy is
currently under scientific evaluation and the EGF 30008 trial
investigating letrozole 6 lapatinib has just been closed to
accrual.
 The bulk of retrospective data and results of the phase III
randomized Trial Beyond Progression show that continuing
trastuzumab after the first disease progression, associated
with a different chemotherapy regimen is superior to the
discontinuation of this agent. With the approval of lapatinib
for the treatment of MBC, the question of continuing
trastuzumab or changing to lapatinib at the time of first
progression remains open
 Lapatinib has shown a significant increase in time to
progression in combination with capecitabine in patients
progressing after trastuzumab.
 Other anti-HER-2 or pan-anti-HER agents, such as
pertuzumab and HKI-272, are currently under investigation
as are combinations of trastuzumab with other biological
agents with or without chemotherapy to tackle the problem
of resistance to trastuzumab.
other biological agents
 Several biological or targeted agents are currently under
active investigation as single agents or in combination.
 Bevacizumab, an anti-angiogenic agent, has been approved by
the FDA and the EMEA for use in combination with
paclitaxel as first-line treatment of MBC. However, a second
randomized phase III trial did not confirm the value of
bevacizumab in an unselected breast cancer population, and
efforts must be made to clearly identify who may benefit from
this expensive therapy. Sunitinib, a potent inhibitor of several
tyrosine kinases, having anti-angiogenic and anti-proliferative
effects, is in phase III trials for both HER-2-negative and
HER-2-positive breast cancer.
response evaluation
 Response evaluation is recommended after 3 months of
endocrine therapy and after two or three cycles of
chemotherapy by clinical evaluation, subjective symptom
evaluation, blood tests and repeating the initially abnormal
radiologic examinations with comparative measures.
However, the interval between assessments should be tailored
to the clinical needs of the patient and to the aggressiveness of
the disease
 Serum tumor markers (CA 15-3) may be helpful in
monitoring response, particularly in the case of not easily
measurable disease, but should not be used as the only
determinant for treatment decision.
 The role of PET/PET–CT in response assessment is still under
investigation.
follow-up
 Follow-up after the treatment of local–regional recurrence
may be carried out as for primary breast cancer.
 Patients with MBC must be seen frequently enough to
provide best possible palliation of symptoms and quality of
life, which means on average every 2–3 months if on
endocrine therapy and every one or two cycles of
chemotherapy.
note
Levels of evidence [I–V] and grades of recommendation [A–D]
as used by the American Society of Clinical Oncology are given
in square brackets. Statements without grading were considered
justified standard clinical practice by the experts and the ESMO
faculty.
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Table 3. Selection of available chemotherapy agents/regimens for MBC
Non-anthracycline-containing
Cyclophosphamide/methotrexate/fluorouracil (CMF)
Platinum-based combinations (e.g. cisplatinum + 5-fluorouracil)
Capecitabine
Vinorelbine
Gemcitabine
Capecitabine + vinorelbine
Vinorelbine 6 gemcitabine
Oral cyclophosphamide with or without methotrexate (metronomic
chemotherapy)
Anthracycline-containing
Epirubicin monotherapy (weekly or 3-weekly)
Doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide
Liposomal doxorubicin with or without cyclophosphamide
Fluorouracil/doxorubicin/cyclophosphamide
Fluorouracil/epirubicin/cyclophosphamide
Taxane-containing
Paclitaxel monotherapy weekly
Docetaxel monotherapy 3-weekly or weekly
Doxorubicin/taxane (paclitaxel or docetaxel)
Epirubicin/taxane (paclitaxel or docetaxel)
Docetaxel/capecitabine
Paclitaxel/gemcitabine
Paclitaxel/vinorelbine
Paclitaxel/carboplatin
New cytotoxic agents
Ixabepilone
Abraxane (nab-paclitaxel)
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